From Liston Street Pulse:
Gilead Sciences Inc. (GILD) said on Wednesday that the European Commission has approved its once-a-day drug Tybost. Tybost is a pharmacokinetic enhancer; meant to improve blood levels of certain HIV treatments. The drug is seen boosting agent for the HIV protease inhibitors (atazanavir 300 mg once daily and darunavir 800 […]
The post Gilead Sciences' Tybost Approved By European Commission appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015